TSC22D4: A Potential Drug Target and Biomarker for the TSC22 Domain Family

Target Name: TSC22D4

NCBI ID: G81628

TSC22D4

TSC22D4: A Potential Drug Target and Biomarker for the TSC22 Domain Family

The TSC22 domain family is a structurally conserved group of proteins that play a crucial role in various cellular processes, including cell signaling, DNA replication, and chromatin remodeling. The TSC22 domain is a transmembrane protein that contains a unique N-terminal region, a unique C-terminal region, and a unique N-terminus region. TSC22D4 is a member of the TSC22 domain family and has been identified as a potential drug target and biomarker.

Potential Drug Target

TSC22D4 is a unique protein that is expressed in various tissues and organs, including brain, heart, liver, and muscle. It is highly expressed in the brain and has been shown to be involved in various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression.

TSC22D4 is a potential drug target because it is involved in various signaling pathways that are disrupted in these disorders. For example, TSC22D4 is involved in the T-cell signaling pathway, which is crucial for the development and function of T cells. TSC22D4 is also involved in the production of reactive oxygen species (ROS), which can damage cellular components and contribute to the development of various diseases.

In addition to its involvement in signaling pathways, TSC22D4 is also a potential biomarker for these disorders. The TSC22 domain is highly conserved across various species, including humans, and is found in various proteins that are involved in cellular processes. Therefore, TSC22D4 may be a useful biomarker for the diagnosis and monitoring of these disorders.

Biomarker Potential

TSC22D4 has been shown to be involved in various signaling pathways that are disrupted in Alzheimer's disease, Parkinson's disease, and depression. For example, studies have shown that TSC22D4 is involved in the production of reactive oxygen species (ROS), which can damage cellular components and contribute to the development of these disorders.

In addition to its involvement in signaling pathways, TSC22D4 may also be a potential biomarker for these disorders. The TSC22 domain is highly conserved across various species, including humans, and is found in various proteins that are involved in cellular processes. Therefore, TSC22D4 may be a useful biomarker for the diagnosis and monitoring of these disorders.

Conclusion

TSC22D4 is a unique protein that is expressed in various tissues and organs and is involved in various cellular processes. Its potential as a drug target and biomarker makes it an attractive target for further research. Further studies are needed to fully understand the role of TSC22D4 in the development and progression of various diseases.

Protein Name: TSC22 Domain Family Member 4

Functions: Binds DNA and acts as a transcriptional repressor (PubMed:10488076). Involved in the regulation of systematic glucose homeostasis and insulin sensitivity, via transcriptional repression of downstream insulin signaling targets such as OBP2A/LCN13 (By similarity). Acts as a negative regulator of lipogenic gene expression in hepatocytes and thereby mediates the control of very low-density lipoprotein release (PubMed:23307490). May play a role in neurite elongation and survival (By similarity)

The "TSC22D4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TSC22D4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets